A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorQilu Pharmaceutical Co., Ltd.
About this trial
This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).
Eligibility criteria
Qualifiers
Voluntarily consent to participate in this study and sign the informed consent form.
Adults ≥18 years, regardless of gender.
ECOG performance status score of 0-1.
Estimated survival time of more than 3 months.
Disqualifiers
Diagnosis of other primary malignancies within 5 years prior to signing the informed consent form.
Prior pathological diagnosis of combined SCLC, or any transformed non-small cell lung cancer or transformed SCLC.
Receipt of chemotherapy within 4 weeks prior to the first administration of study drug, or receipt of radiotherapy, biologics, endocrine therapy, immunotherapy, or other anti-tumor therapy within 4 weeks prior to the first dose.
Previous or ongoing treatment with topoisomerase I inhibitors, including antibody-drug conjugates (ADCs) containing topoisomerase I inhibitor payloads.
Trial design
Treatments tested in this trial
- MHB088C for Injection
- Topotecan
- Irinotecan
- Paclitaxel
Treatment groups
450 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov